TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24150779

Group type: EXPERIMENTAL
Intervention: BG-12 240 mg twice daily (BID)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: BG-12 240 mg three times daily (TID)
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1237
Study: 22007026

Group type: EXPERIMENTAL
Intervention: Multifactorial treatment (lifestyle and drug, including atorvastatin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (LDL-C target < 130 mg/dL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multifactorial treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 20868531

Group type: EXPERIMENTAL
Intervention: Multifactorial adherence-based intervention (motivational interviews, pill reminders, family support, blood pressure self-recording, simplification of dosing regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18604566

Group type: EXPERIMENTAL
Intervention: Multimodal group therapy program (20 treatment days over 10 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting list control group (13 patients)
Number of subjects: 24
Study: 15796645

Group type: EXPERIMENTAL
Intervention: Standard treatment with contingency management (CM) for 12 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 77
Study: 12452760

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study: 10522578

Group type: EXPERIMENTAL
Intervention: mepivacaine 1% with 1 ml saline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: mepivacaine 1% with 5 ml saline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: mepivacaine 1% with 10 ml saline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: mepivacaine 1.5% with 1 ml saline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: mepivacaine 1.5% with 5 ml saline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: mepivacaine 1.5% with 10 ml saline
Number of subjects: 152
Study: 8557965

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g elemental calcium given twice a day for 16 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1834592

Group type: EXPERIMENTAL
Intervention: 30 mg pantoprazole injected over 2 min on 5 consecutive days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administered i.v. on 2 consecutive days
Number of subjects: 8
Study: 7009594

Group type: EXPERIMENTAL
Intervention: Weekly coated‐charcoal hemoperfusion (CCHP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham hemoperfusion (Sham HP)
Number of subjects: 6
Study: 30791795

Group type: EXPERIMENTAL
Intervention: Free Drug Program (FDP)
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Home drug delivery
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Long-lasting injection treatment
Number of subjects: 2007
Study: 28272202

Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia (CEGA)
Number of subjects: 144
Study: 26192183

Group type: EXPERIMENTAL
Intervention: Hypocaloric Mediterranean type of diet and physical activity intervention (D+PA)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Physical activity intervention alone (PA)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 342
Study: 23429100

Group type: EXPERIMENTAL
Intervention: N-MUF (3000 ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no N-MUF)
Number of subjects: 50
Study: 21409669

Group type: EXPERIMENTAL
Intervention: Empathy-arousing messages
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Fear-arousing messages
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 260
Study: 19075045

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) with acidic beverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) with higher gastric pH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) plus nutritional supplement (Boost)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg) plus nutritional supplement (Boost)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) before high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) during high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) after high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased gastric motility
Number of subjects: 0
Study: 17488963

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Intensive anti-ischemic drug therapy
Number of subjects: 201
Study: 15535796

Group type: EXPERIMENTAL
Intervention: Generalized social phobia participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study: 11133616

Group type: EXPERIMENTAL
Intervention: Profile Soft-Seal Cuff (PSSC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Profile Cuff (PC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Trachelon
Number of subjects: 45
Study: 9439908

Group type: EXPERIMENTAL
Intervention: T4 treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7533703

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 2962993

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29529650

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Miniposterior Approach (MPA)
Number of subjects: 101
Study: 27838739

Group type: EXPERIMENTAL
Intervention: Early dyspnea improvement measured by Likert scale during the first 24 hours
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Dyspnea improvement over the first 5 days measured by visual analog scale area under the curve (VAS AUC)
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: General wellbeing improvement measured by Likert scale
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: General wellbeing improvement measured by VAS score
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Multi-variable predictors of moderate or marked dyspnea improvement
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Efficacy of serelaxin
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: In-hospital and post-discharge clinical outcomes
Number of subjects: 1161
Study: 26328771

Group type: EXPERIMENTAL
Intervention: Staff training intervention to improve patient engagement in activities
Number of subjects: 0
Study: 23146135

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 6 months
Number of subjects: 50
Study: 21513078

Group type: EXPERIMENTAL
Intervention: Preemptive alveolar recruitment strategy (ARS) with 10 manual breaths at 40 cmH2O and PEEP of 15 cmH2O until OLV commenced.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with tidal volume of 10 ml kg(‐1).
Number of subjects: 42
Study: 18313637

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) use
Number of subjects: 422

Group type: COMPARATOR
Intervention: Male condom use
Number of subjects: 422

Group type: COMPARATOR
Intervention: No contraceptive method
Number of subjects: 422
Study: 16239594

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)
Number of subjects: 309

Group type: COMPARATOR
Intervention: None (control group: women without T2DM or MS)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS) alone
Number of subjects: 309
Study: 12611772

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glutamine-rich protein supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 8
Study: 10390376

Group type: EXPERIMENTAL
Intervention: 100 ppb O3
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 200 ppb NO2
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 ppb O3 + 200 ppb NO2
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 200 ppb O3
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 400 ppb NO2
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 200 ppb O3 + 400 ppb NO2
Number of subjects: 11

Group type: COMPARATOR
Intervention: Air
Number of subjects: 11
Study: 8862681

Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 0
Study: 1712735

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 5,000 IU hCG
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intramuscular injection of 5,000 IU hCG
Number of subjects: 24
Study: 6131223

Group type: EXPERIMENTAL
Intervention: Airway cooling during exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respiratory heat exchange
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mast-cell mediators
Number of subjects: 0
Study: 30507241

Group type: EXPERIMENTAL
Intervention: Vocational Coach (VC) condition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard Coach + VR condition
Number of subjects: 32
Study: 27418129

Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 37

Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 37
Study: 25470087

Group type: EXPERIMENTAL
Intervention: Aripiprazole long-acting injection (LAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23872254

Group type: EXPERIMENTAL
Intervention: Red ginseng extract (RGE) 1500 mg orally three times a day for 7 days
Number of subjects: 15
Study: 19965813

Group type: EXPERIMENTAL
Intervention: Reg6M (6-month regimen: 2EHRZ(3)/4HR(3))
Number of subjects: 327

Group type: COMPARATOR
Intervention: Reg9M (9-month regimen: 2EHRZ(3)/7HR(3))
Number of subjects: 327
Study: 18759293

Group type: EXPERIMENTAL
Intervention: Ocrelizumab plus MTX
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (doses of 200 mg and higher) plus MTX
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (10 mg and 50 mg)
Number of subjects: 237
Study: 15710271

Group type: EXPERIMENTAL
Intervention: Tailored dietary feedback, brief telephone counseling, nutritional education booklets
Number of subjects: 754

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 754
Study: 14523139

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 1058
Study: 10757543

Group type: EXPERIMENTAL
Intervention: Diet rich in alpha-linolenic acid (8.3 g/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet rich in oleic acid
Number of subjects: 12
Study: 8922306

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine supplementation (600 mg daily for 3-9 months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no N-acetylcysteine supplementation)
Number of subjects: 33
Study: 1311872

Group type: EXPERIMENTAL
Intervention: Medium-cuff group (7 cm from the dentate line)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Minimum-cuff group (2 cm cuff above the levator)
Number of subjects: 16
Study: 4002807

Group type: EXPERIMENTAL
Intervention: 20 mg muzolimine once daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: 2.5 mg indapamide once daily
Number of subjects: 53
Study: 31797880

Group type: EXPERIMENTAL
Intervention: Post-dilution hemodiafiltration (HDF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rexsys and VIE-A in both HD and HDF
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All dialyzers
Number of subjects: 32

Group type: COMPARATOR
Intervention: TDC vs PDC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rexsys
Number of subjects: 32
Study: 29385054

Group type: EXPERIMENTAL
Intervention: Low d‐allulose (4 g × 2 times/day)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High d‐allulose (7 g × 2 times/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (sucralose, 0.012 g × 2 times/day)
Number of subjects: 121
Study: 28066101

Group type: EXPERIMENTAL
Intervention: Montelukast-levocetirizine (10 mg and 5 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Montelukast-fexofenadine (10 mg and 120 mg)
Number of subjects: 70
Study: 24702629

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 528

Group type: COMPARATOR
Intervention: Usual care (unfractionated heparin or placebo)
Number of subjects: 528
Study: 24331776

Group type: EXPERIMENTAL
Intervention: Dietary weight management program
Number of subjects: 88
Study: 21175438

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe with dalcetrapib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcetrapib with ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dalcetrapib alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ezetimibe alone
Number of subjects: 0
Study: 18769692

Group type: EXPERIMENTAL
Intervention: Pharmacist-directed care
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Pharmacist collaborative care
Number of subjects: 2060
Study: 16427490

Group type: EXPERIMENTAL
Intervention: Epidural injection of 80 mg methylprednisolone acetate and 10 mg bupivacaine
Number of subjects: 598

Group type: COMPARATOR
Intervention: Standard therapy (oral antivirals and analgesics)
Number of subjects: 598
Study: 14650210

Group type: EXPERIMENTAL
Intervention: mexidol, intravenously instilled in a daily dose of 2‐4 mg/kg over a period of 10 days in combination with a standard neurometabolic scheme
Number of subjects: 90
Study: 10929903

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis with active inflammation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis in remission
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis with dysplasia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Controls (normal colonoscopy)
Number of subjects: 62
Study: 9459674

Group type: EXPERIMENTAL
Intervention: oligoantigenic diet
Number of subjects: 21
Study: 1632718

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 4061344

Group type: EXPERIMENTAL
Intervention: 100 micrograms of selenite
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 100 micrograms of yeast-Se
Number of subjects: 200

Group type: COMPARATOR
Intervention: No Se supplements (control)
Number of subjects: 200
Study: 31050933

Group type: EXPERIMENTAL
Intervention: Diode laser (DL) as an adjunct to Kirkland flap surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Kirkland flap surgery alone
Number of subjects: 20
Study: 29179625

Group type: EXPERIMENTAL
Intervention: Pediatric malaria vaccine trial (GSK/PATH‐MVI RTS,S)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Integration of research into health care services
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Implementation of research
Number of subjects: 52
Study: 27036101

Group type: EXPERIMENTAL
Intervention: Simulation-based education with fever education brochures
Number of subjects: 160

Group type: COMPARATOR
Intervention: Brochure only (Control group)
Number of subjects: 160
Study: 25243680

Group type: EXPERIMENTAL
Intervention: STOPP/START medication intervention
Number of subjects: 359

Group type: COMPARATOR
Intervention: Usual pharmaceutical care
Number of subjects: 359
Study: 22526437

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of lidocaine 20 mg and nitroglycerin 0.1 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 90
Study: 20952014

Group type: EXPERIMENTAL
Intervention: Incontinence Impact Questionnaire
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: International Consultation on Incontinence Questionnaire
Number of subjects: 597
Study: 17610056

Group type: EXPERIMENTAL
Intervention: Levosimendan (24‐h infusion of 0.1 mug/kg/min)
Number of subjects: 63
Study: 18444445

Group type: EXPERIMENTAL
Intervention: LDFA (70‐100 microg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IDFA (23‐30 microg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SDFA (2‐4 microg/kg)
Number of subjects: 60
Study: 15363826

Group type: EXPERIMENTAL
Intervention: Amlodipine-atorvastatin combination
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 45
Study: 11327507

Group type: EXPERIMENTAL
Intervention: Surface-marker imaging system measuring rotational axis pathway (RAP)
Number of subjects: 10
Study: 9143085

Group type: EXPERIMENTAL
Intervention: LoFric catheter
Number of subjects: 14

Group type: COMPARATOR
Intervention: EasiCath catheter
Number of subjects: 14
Study: 8194616

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC), 100 mg from days 2 to 6
Number of subjects: 30

Group type: COMPARATOR
Intervention: Natural cycle (no treatment)
Number of subjects: 30
Study: 3538962

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg orally every 12 hours
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 68
Study: 30711429

Group type: EXPERIMENTAL
Intervention: Health education with videos and leaflets
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 144
Study: 28758127

Group type: EXPERIMENTAL
Intervention: Inappropriate use of diagnostic tests and treatment of bronchiolitis
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Number of siblings
Number of subjects: 303
Study: 27771572

Group type: EXPERIMENTAL
Intervention: 50 mg of d-Cycloserine (DCS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Matched placebo capsule
Number of subjects: 51
Study: 24825029

Group type: EXPERIMENTAL
Intervention: Home-based intervention (n=143)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Clinic-based intervention (n=137)
Number of subjects: 280
Study: 21438101

Group type: EXPERIMENTAL
Intervention: Thiopurines (azathioprine and 6-mercaptopurine)
Number of subjects: 43
Study: 18691705

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 33

Group type: COMPARATOR
Intervention: Simple sugars
Number of subjects: 33
Study: 17210332

Group type: EXPERIMENTAL
Intervention: Sevoflurane/fentanyl
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 46
Study: 16322383

Group type: EXPERIMENTAL
Intervention: 6 months of recombinant human GH (rhGH) at 0.2 IU/kg per week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12087344

Group type: EXPERIMENTAL
Intervention: St John's wort (single dose 900 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: St John's wort (long-term treatment 300 mg 3 times a day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Fexofenadine (untreated phase)
Number of subjects: 3
Study: 9464430

Group type: EXPERIMENTAL
Intervention: Tc‐99m tetrofosmin scintimammography
Number of subjects: 44

Group type: COMPARATOR
Intervention: Plain‐film mammography
Number of subjects: 44
Study: 8591802

Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2612091

Group type: EXPERIMENTAL
Intervention: Oral cyclosporin A (CyA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 343062

Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large muscle exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonhyperactive control
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attentional-training placebo
Number of subjects: 0
Study: 31858264

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group cognitive-behavioral therapy (CBT) or sertraline
Number of subjects: 40
Study: 30997411

Group type: EXPERIMENTAL
Intervention: Provider and patient education and provider feedback via biweekly, unblinded normative comparison
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 192
Study: 28284655

Group type: EXPERIMENTAL
Intervention: Video and text instructions for eyelid laceration repair
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Video and text instructions for blepharoplasty
Number of subjects: 16

Group type: COMPARATOR
Intervention: Text instructions alone for eyelid laceration repair
Number of subjects: 16

Group type: COMPARATOR
Intervention: Text instructions alone for blepharoplasty
Number of subjects: 16
Study: 25517204

Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine daily for 8 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 59
Study: 23352604

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus XELIRI (irinotecan 200mg/m² on day 1 and oral capecitabine 1,000 mg/m² bid on days 1-14)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI (5-fluorouracil 400mg/m² on day 1 plus 2,400 mg/m² as a 46-h infusion, leucovorin 400mg/m² on day 1, and irinotecan 180 mg/m² on day 1)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 145

Group type: COMPARATOR
Intervention: Bevacizumab-XELIRI
Number of subjects: 145

Group type: COMPARATOR
Intervention: Bevacizumab-FOLFIRI
Number of subjects: 145
Study: 21205360

Group type: EXPERIMENTAL
Intervention: Milk supplementation (1000 mg Ca/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (isoenergetic)
Number of subjects: 25